click here to return to the Consilient Health home page
Welcome to Consilient Health
 
Search the site
Search Site
*lhs menu
My Consilient      
Generics      
How to Order?      
Press Release
CONSILIENT HEALTH ADVANCES IN THE UK, LAUNCHING MAJOR NEW PRODUCT AND INTERNET PORTAL FOR GENERIC DRUGS

12 December 2005 - Consilient Health Consolidates Position in UK With
First-To-Market Launch of Major Patent-Free Drug


Consilient Health, which entered the competitive European market for off-patent medicines less than 8 months ago, today announced that it is consolidating its position in the UK with the simultaneous launches of Lansoprazole, following expiry of its exclusivity patent on 10 December, and of its innovative pharmaceutical trading portal for distributors. Lansoprazole, which was launched in the UK market under the Zoton® trademark in 1994, recorded sales in Great Britain during the past twelve months of almost £300 million.

"Consilient has spent four years preparing its entry into the European pharmaceutical market", said Douglas B. Andrews, Founder and CEO of Consilient Health. "We're determined to strengthen our existing position in the UK and Europe, and we look forward to enhancing the customer loyalty which our innovative business model, products and services - already known for their high quality, reliability and competitive pricing - do not fail to deliver".

Consilient Health has carved a unique niche in the European markets which it has entered to date, including the UK, Scandinavia and the Netherlands, by committing to provide the best available healthcare at the most affordable prices, and by guaranteeing peace of mind to distributors with a completely reliable supply record.

Earlier this year, Consilient Health made its debut on the UK market by launching two new generics - Lamotrigine in July and Terbinafine in August. The launch of Lansoprazole will consolidate Consilient's position the UK and ensure a greater share of the overall generics market.

Decades of multi-national managerial experience in the pharmaceutical and healthcare industries have enabled the Consilient Health management team to create and launch a uniquely innovative and ground-breaking business model to enable pharmaceutical distributors to optimise state of the art quality, efficient and cost-effective supply chain management. Significant costs savings are shared with national governments, business partners and patients, contributing to the fast growth and success of the company.

The latest example of Consilient's forward-thinking innovative strategy, also being launched today, is a novel business-to-business web based trading platform, enabling the company to supply distributors in the UK, ensuring fast and reliable access to the products they need when they need them.
For more information contact:
press@consilienthealth.com
http://www.consilienthealth.com
Tel.: +353 (0) 1 2057760
About Consilient
Consilient Health, Ltd. markets and distributes generic pharmaceuticals utilising a large network of manufacturers and business partners. Consilient Health is a reliable, committed and trustworthy generic pharmaceutical company that strives to promote and distribute high quality generic pharmaceuticals at affordable prices.

Additional information about Consilient Health may be obtained through their website at www.consilienthealth.com
What are Generics? - Generic medicines contain the same active ingredients as the original brand name drugs and are therefore interchangeable with the originator product. Generics are used for the same symptoms as the original drug and are bio-equivalent. They provide the same quality, safety and efficacy as the original brand name product and undergo strict audits before being licensed and given market approval by EU or national medicines authorities.

New drugs enjoy patent protection for at least 20 years, which gives the manufacturer the exclusive right to market and sell their drug, and to receive a very high return on their original investment in R&D. Once the patents on new drugs expire, competing drug companies can apply to manufacture the same drug as its generic equivalent. After a generic drug obtains approval, increased competition keeps the price down.
Patient Empowerment - Patients are increasingly asking for the generic version of popular branded drugs at their local pharmacy. Generic drugs are instrumental in providing low cost choice without sacrificing quality, safety or efficacy.
Generic Drugs in Europe - Government funded national healthcare plans stand to reap huge benefits from large-scale use of generic medicines when caring for their elderly and chronically ill citizens. Using generic drugs entails substantial savings for governments, so they can maintain a high level of care despite an increasingly aging population.
The European Market - The generic drug market in Europe is in a position to experience substantial market growth. Generics in some member states can account for up to 50% of all prescriptions and this is forecast to reach 60% by 2007. Pressures to contain costs on healthcare services and organisations will lead to amplified implementation of generic replacement and prescribing practices in many EU Member States. Patent expiry of leading drugs and EU enlargement are inherent in the growth and expansion of the EU generics sector to 2007.
Latest News
Latest News Flag
Consilient Health launches Losartan
2nd March 2010
Consilient Health is proud to announce the launch of its Losartan potassium 12.5/25/50/100mg film-coated tablets and Losartan potassium/ Hydrochlorothiazide 50/12.5mg and 100/25mg film-coated tablets in blister packs of 28's.
closing dotted line
Latest News Flag
Consilient Health launches Levocetirizine
28th September 2009
closing dotted line
Latest News Flag
Consilient Health 1st to Market Again! Clopidogrel 75mg f/c Tablets
1st July 2009
more...
closing dotted line
Latest News Flag
Consilient Health launches Pantoprazole
6th May 2009
closing dotted line
Latest News Flag
Consilient Health elected member of British Generic Manufacturers Association (BGMA)
21st January 2009
closing dotted line
Latest News Flag
Consilient Health launches Alventa XL (Venlafaxine)
8th December 2008
closing dotted line
Latest News Flag
Consilient Health launches Rawel XL (Indapamide)
22nd September 2008
closing dotted line
Latest News Flag
Consilient Health launches Bicalutamide
8th July 2008
closing dotted line
Latest News Flag
Consilient Health launches Mirtazapine Orodispersible Tablets
13th June 2008
closing dotted line
Latest News Flag
Consilient Health launches Perindopril
29th May 2008
closing dotted line
Latest News Flag
Nazdol MR Tablets - UK 1st to market success for Consilient Health!
5th March 2008
more...
closing dotted line
Latest News Flag
Consilient Health launches Risperidone
10th December 2007
closing dotted line
Latest News Flag
Consilient Health launches Amlodipine
2nd October 2007
closing dotted line
Latest News Flag
Consilient Health launches Alendronic Acid
5th September 2007
closing dotted line
Latest News Flag
Consilient Health launches Carvedilol
5th September 2007
closing dotted line
Latest News Flag
Consilient Health launches Mirtazapine
24th July 2007
closing dotted line
Latest News Flag
Consilient Health launches Finasteride
29th May 2007
closing dotted line
Latest News Flag
Consilient Health launches Glimepiride
16th October 2006
closing dotted line
Latest News Flag
Consilient Health launches Sumatriptan
22nd May 2006
closing dotted line
Latest News Flag
Consilient Health launches Sertraline
9th May 2006
closing dotted line
Latest News Flag
Consilient Health launches Tamsulosin
13th April 2006
closing dotted line
Latest News Flag
Consilient Health launches Omeprazole
6th March 2006
closing dotted line
Latest News Flag
Consilient Health launches Lansoprazole
12th December 2005
more...
closing dotted line
Latest News Flag
Consilient Health elected member of European Generics Association (EGA)
21st November 2005
closing dotted line
Latest News Flag
Consilient Health receives Wholesale Dealers License
19th September 2005
closing dotted line
Latest News Flag
Consilient Health launches Terbinafine
2nd September 2005
closing dotted line
Latest News Flag
Consilient Health launches Lamotrigine
26th July 2005
closing dotted line
Latest News Flag
Consilient Health enters UK and Dutch Market
26th July 2005
more...
closing dotted line
Latest News Flag
First product release in Denmark
9th May 2005
closing dotted line